Gland Pharma’s stock jumped by over 12% on November 5, 2024, after the company announced its second-quarter fiscal 2025 results, which aligned with market expectations despite a year-over-year dip in profits.
The company’s consolidated net profit dropped by 16% to ₹163.53 crore for the quarter ending September 30, 2024, matching analysts’ expectations of around ₹162.9 crore. This is a decrease from ₹194.08 crore recorded in the same period last year.
A significant factor affecting the company’s profitability has been the rising cost of raw materials, which increased to 39.2% of total sales from 37.9% in the previous year. This increase contributed to a contraction in Gland Pharma’s EBITDA margin, which fell to 21.1% from 24% a year earlier.
As of 1:38 pm, Gland Pharma’s shares were trading 12.13% higher at ₹1,806.30 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.
